Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Design, synthesis, and evaluation

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1649-1667

  Harmange, Jean Christophe ^a   Weiss, Matthew M ^a   Germain, Julie ^a   Polverino, Anthony J ^a   Borg, George ^a   Bready, James ^a   Chen, Danlin ^a   Choquette, Deborah ^a   Coxon, Angela ^a   DeMelfi, Tom ^a   DiPietro, Lucian ^a   Doerr, Nicholas ^a   Estrada, Juan ^a   Flynn, Julie ^a   Graceffa, Russell F ^a   Harriman, Shawn P ^a   Kaufman, Stephen ^b   La, Daniel S ^a   Long, Alexander ^a   Martin, Matthew W ^a   Neervannan, Sesha ^a,c   Patel, Vinod F ^a   Potashman, Michele ^a   Regal, Kelly ^a   Roveto, Phillip M ^a   Schrag, Michael L ^a   Starnes, Charlie ^a   Tasker, Andrew ^a   Teffera, Yohannes ^a   Wang, Ling ^a   White, Ryan D ^a   Whittington, Douglas A ^a   Zanon, Roger ^a   more..

^a AMGEN INC   (United States)

^b Amgen Inc ^*

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (3 METHYLISOXAZOL 5 YL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (PYRIDIN 2 YL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (PYRIDIN 3 YL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (PYRIDIN 4 YL) 1 NAPHTHAMIDE; N (4 CHLOROPHENYL) 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 5 FLUORO 1 NAPHTHAMIDE; N (4 CHLOROPHENYL)6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; NAPHTHAMIDE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149086287     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701097z     Document Type: Article

References (53)

1. (a) Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2, 795-803.
2. (b) Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653-660.
3. (a) Cherrington, J. M.; Strawn, L. M.; Shawver, L. K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res. 2000, 79, 1-38.
4. (b) Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004, 100, 2491-2499.
5. Fava, G. A. Affective disorders and endocrine disease. New insights from psychosomatic studies. Psychosomatics 1994, 35, 341-353.
6. Walsh, D. A.; Haywood, L. Angiogenesis: a therapeutic target in arthritis. Curr. Opin. Invest. Drugs 2001, 2, 1054-1063.
7. Aiello, L. P.; Avery, R. L.; Arrigg, P. G.; Keyt, B. A.; Jampel, H. D.; Shah, S. T.; Pasquale, L. R.; Thieme, H.; Iwamoto, M. A.; Park, J. E.; et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994, 331, 1480-1487.
8. Detmar, M. The role of VEGF and thrombospondins in skin angiogenesis. J. Dermatol. Sci. 2000, 24 (Suppl. 1), S78-S84.
9. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175, 409-416.
10. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
11. (a) Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C.; Gospodarowicz, D.; Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
12. (b) Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60, 203-212.
13. (c) Shinkaruk, S.; Bayle, M.; Lain, G.; Deleris, G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 95-117.
14. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
15. Cardones, A. R.; Banez, L. L. VEGF inhibitors in cancer therapy. Curr. Pharm. Des. 2006, 12, 387-394.
16. D'Adamo, D. R.; Anderson, S. E.; Albritton, K.; Yamada, J.; Riedel, E.; Scheu, K.; Schwartz, G. K.; Chen, H.; Maki, R. G. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 2005, 23, 7135-7142.
17. Adjei, A. A. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. Clin. Lung Cancer 2007, 8 (Suppl. 2), S74-S78.
18. (a) Thomas, A. L.; Morgan, B.; Dreves, J.; Unger, C.; Wiedenmann, B.; Vanhoefer, U.; Laurent, D.; Dugan, M.; Steward, W. P. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin. Oncol. 2003, 30 (Suppl. 6), 32-38.
19. (b) Ryan, A. J.; Wedge, S. R. ZD6474-A novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 2005, 92 (Suppl. 1), S6-S13.
20. (c) Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46, 1116-1119.
21. (d) Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl) indeno[2,1-a]pyrrolo[3,4-c] carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
22. (e) Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
23. (f) Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Aimone, L.; Klein-Szanto, A.; Herbet, J.-M.; Bono, F.; Schaeffer, P.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Vaught, J.; Mallamo, J.; Dionne, C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003, 63, 5978-5991.
24. (g) Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63, 7301-7309.
25. (a) Cohen, M. H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007, 12, 356-361.
26. (b) Culy, C. Bevacizumab: antiangiogenic cancer therapy. Drugs Today 2005, 41, 23-36.
27. (c) Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
28. Giaccone, G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin. Cancer Res. 2007, 13, 1961-1970.
29. (a) Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discovery 2006, 5, 279-280.
30. (b) Fiedler, W.; Serve, H.; Doehner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105 (3), 986-993.
31. Goodman, V. L.; Rock, E. P.; Dagher, R.; Ramchandani, R. P.; Abraham, S.; Gobburu, J. V. S.; Booth, B. P.; Verbois, S. L.; Morse, D. E.; Liang, C. Y.; Chidambaram, N.; Jiang, J. X.; Tang, S.; Mahjoob, K.; Justice, R.; Pazdur, R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 2007, 13, 1367-1373.
32. (a) Bukowski, R.; Cella, D.; Gondek, K.; Escudier, B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am. J. Clin. Oncol. 2007, 30, 220-227.
33. (b) Flaherty, K. T. Sorafenib in renal cell carcinoma. Clin. Cancer Res. 2007, 13, 747s-752s.
34. Strumberg, D.; Clark, J. W.; Awada, A.; Moore, M. J.; Richly, H.; Hendlisz, A.; Hirte, H. W.; Eder, J. P.; Lenz, H.-J.; Schwartz, B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12, 426-437.
35. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006, 66, 8715-8721.
36. Potashman, M. H.; Bready, J.; Coxon, A.; DeMelfi, T. M., Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J.-C.; Kaufman, S. A.; Kendall, R.; Kim, J. L.; Kumar, G. N.; Long, A. M.; Neervannan, S.; Patel, V. F.; Polverino, A.; Rose, P.; vander Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem. 2007, 50, 4351-4373.
37. Hodous, B. L.; Geuns-Meyer, S. D.; Hughes, P. E.; Albrecht, B. K.; Bellon, S.; Caenepeel, S.; Cee, V. J.; Chaffee, S. C.; Emery, M.; Fretland, J.; Gallant, P.; Gu, Y.; Johnson, R. E.; Kim, J. L.; Long, A. M.; Morrison, M.; Olivieri, P. R.; Patel, V. F.; Polverino, A.; Rose, P.; Wang, L.; Zhao, H. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 2886-2889.
38. Aminobenzoxazoles exhibited potent inhibition of KDR in our enzyme assay; however, the 2-aminobenzoxazoles were considerably less potent when tested in our human umbilical vein endothelial cell assay (60-fold enzyme to cell shift). While incorporation of a basic solubilizing group afforded improved cellular potency, it also resulted in compounds with inferior pharmacokinetic properties, such as large volumes of distribution and high plasma clearance levels.
39. Pyridylpyrimidine 5 lacks selectivity and is equipotent against KDR and Tie-2.
40. (a) He, M.; Kania, R. S.; Lou, J.; Zhou, R. Preparation of Naphthalenecarboxamides and Their Derivatives as New Antiangiogenic Agents. WO 2005/021553 A1, 2005.
41. (b) Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J.-C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A. Preparation of Heteroaryl Substituted Naphthalenes as Inhibitors of Lck, VEGFR and/or HGF Related Activity. WO 2005/070891 A2, 2005.
42. Protection of the carboxylic acid was necessary to achieve fluorination of the naphthyl ring in moderate yield.
43. Thomas, A. P.; Hennequin, L. F. A.; Ple, P. A. Quinoline Derivatives Inhibiting the Effect of Growth Factors Such as VEGF. WO 1998/13350 A1, 1998.
44. Pierce, A. C.; Sandrettio, K. L.; Bemis, G. W. Kinase inhibitors and the case for CH-O hydrogen bonds in protein-ligand binding. Proteins: Struct., Funct., Genet. 2002, 49, 567-576.
45. Weiss, M. M.; Harmange, J.-C.; Polverino, A. J.; Bauer, D.; Berry, L.; Berry, V.; Borg, B.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Whittington, D.; Zanon, R. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J. Med. Chem. 2008, 51, 1668-1680.
46. Compounds formulated in OraPlus were administered as solutions; however, when formulated in Tween/HPMC, compounds were administered as suspensions.
47. 14C copper cyanide.
48. (a) Lanza, D. L.; Code, E.; Crespi, C. L.; Gonzalez, F. J.; Yost, G. S. Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human Cyp2F1 expressed in lymphoblastoid cells. Drug Metab. Dispos. 1999, 27, 798-803.
49. (b) Gram, T. E. Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol. Rev. 1997, 49, 298-341.
50. m of ATP with respect to 1 μM peptide substrate.
51. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27, 1350-1359.
52. Miles, A. A.; Miles, E. M. Vascular reactions to histamine, histamine-liberator, and leukotaxine in the skin of guinea pigs. J. Physiol. 1952, 118, 228-257.
53. Coxon, A.; Bolon, B.; Estrada, J.; Kaufman, S.; Scully, S.; Rattan, A.; Duryea, D.; Hu, Y. L.; Rex, K.; Pacheco, E.; Van, G.; Zack, D.; Feige, U. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 2002, 46, 2604-2612.